南昌地区汉族健康人群中抗A(B)抗体效价检测分析

目的探讨南昌地区汉族健康人群(献血人群和孕妇)中IgM和IgG抗A、抗B抗体效价的范围。方法 ABO正反定型和RhD血型鉴定均采用试管凝集法;抗体筛选和抗体筛选鉴定用盐水、凝聚胺法进行抗体筛选;抗体筛选阳性再用谱细胞于盐水、凝聚胺和抗人球蛋白介质中进行抗体鉴定;采用盐水倍比稀释直接离心试管法检测IgM抗A(B)抗体效价,用2-Me灭活IgM抗A(B)后,用凝聚胺法进行IgG抗A或抗B的血型抗体效价检测。结果 A:B:O=41:26:138;RhD阴性9例;85例孕妇中IgG抗A(B)效价≥64为8.4%(10/119),而120例无偿献血者和孕妇的丈夫IgG抗A(B)效价≥64为4.1%(8/193),IgM抗A(B)效价≥64为32.6%(61/187);孕妇IgG抗A(B)效价高的人数比其他健康人要多且均为O型。结论 A型和B型的人大多数是IgM为主,成年O型人血清中IgG抗A和抗B占有优势,尤其是有妊娠史或流产史的女性。为进一步探讨本地区IgM和IgG抗A、抗B抗体效价的高低与身体不同健康状态及某些疾病相关性提供了一定的参考价值。为南方汉族健康人群IgG抗A(B)效价提供参考。     

O型孕妇产前IgG血型抗体效价监测及意义

目的：了解O型孕妇的血型抗体IgG抗A （B）效价与新生儿溶血病之间的关系,为进一步提高孕妇产前IgG抗A（B）效价检测率、预防新生儿溶血病提供依据。方法采集ABO血型为O型的孕妇及其丈夫（ABO血型为非O型）静脉血抗凝和不抗凝管,进行抗人球蛋白试验,检测孕妇血清中针对其丈夫红细胞上血型抗原存在的IgG抗A（B）抗体的效价,分析各血型抗体效价大于或等于64所占比例;分析孕产次数与抗体效价之间的关系。结果检测O型孕妇957例,抗体效价大于或等于64有635例,占66．3％。其中A型血共476例,抗体效价大于或等于64有357例,占A型的75．0％;B型血共339例,抗体效价大于或等于64有200例,占B型的59．0％;AB型血共142例,抗体效价大于或等于64有78例,占AB型的54．9％。孕产次数与IgG抗A（B）效价呈正相关性,随着孕产次数的增多,抗体效价大于或等于64的比例显著增加。结论孕妇IgG抗A （B）抗体效价高,发生新生儿溶血病的可能性大,且母亲体内IgG抗A（B）高效价与新生儿溶血病发生率成呈相关性。妊娠期间对O型血的孕妇进行该项检测具有重要意义。     

孕母血型抗体与新生儿ABO溶血病发生的相关性分析

目的探讨产前血型抗体与ABO新生儿溶血病发病（HDN）的相关性。方法对132例O型母亲行产前血型抗体效价检测,新生儿出生后检测血型血清学及胆红素水平,综合评价孕母血型抗体与新生儿ABO溶血病发生的相关性。结果132例夫妻ABO血型不合调查中,O型妻子,A型、B型、AB型丈夫各组发生HDN阳性率分别为38%、38%、26%（P〉0.01）,无统计学意义;孕妇IgG抗-A（B）效价为≤32、64、1282、56和≥512各组HDN阳性率分别为3%、25%、57%和86%、90%（P〈0.01）;132例非O型新生儿组血清总胆红素及间接胆红素分别为42.06±15.02μmol/L和34.56±16.82μmol/L,60例O型新生儿组血清总胆红素及间接胆红素分别为33.04±7.3μmol/L和26.99±9.32μmol/L（P〈0.05）。结论HDN的发生与丈夫血型无关。孕妇血清中IgG抗-A（B）效价越高,ABO-HDN的发生率越高,且随抗体效价增高而增高。发生HDN,新生儿血清总胆红素及间接胆红素也相应增高。     

ABO血型不合的夫妇产前血型抗体效价测定在产前诊断中的意义

[目的]通过对ABO血型不合的孕妇血清中血型抗体效价的测定,了解异常IgG抗A／B的分布情况及临床意义,为预防治疗新生儿溶血病（HDN）提供重要的实验依据。[方法]选择夫妇ABO血型不合者660例,采用微柱凝胶法进行IgG抗A／抗B的ABO血型抗体效价检测。[结果]660例ABO血型不合的孕妇血清中,IgG抗A／抗B效价〉1：64者170人,占25．8％,且抗体的效价与妊娠年龄及妊娠次数呈正相关。[结论]O型血孕妇与丈夫血型不合时,产前应及时检测血清中IgG抗体水平,及早发现及时治疗,可减少由于母婴血型不合引起的新生儿溶血性疾病的发生。     

孕妇产前IgG抗A(B)效价与新生儿溶血

目的探讨孕妇产前抗A(B)抗体效价与新生儿溶血病的关系。方法对884例孕妇为O型,丈夫为非O型者的孕妇进行产前抗A(B)IgG抗体效价测定,观察产后是否发生溶血;同时选择我院NICU住院的新生儿ABO溶血病患者34例,测定血清总胆红素,并与母亲产前抗A(B)抗体效价比较分析。结果IgG类抗A、抗B效价≥64的O/A、O/B、O/AB(抗A)、O/AB(抗B)的孕妇所占比例分别为81.1%、71.4%、74.5%、69.6%,O/A组显著高于O/B和O/AB(抗B)组(P<0.01),其他组间差异无显著性(P>0.05);随着孕妇血清IgG抗A(B)抗体效价的升高,新生儿溶血发生率存在显著性差异(P<0.01);34例NICU住院的新生儿ABO溶血病患者血清总胆红素浓度水平与孕妇血清IgG抗A(B)抗体效价差异无显著性(P>0.05)。结论孕妇产前ABO血清IgG抗A(B)效价测定可作为判断胎儿出生后是否发生新生儿溶血病的筛查指标。对降低新生儿母婴血型不合引起的溶血病具有积极作用。     

孕妇产前血清IgG抗A（B）抗体效价对ABO新生儿溶血病的诊断意义——附466例检测报告

目的：探讨孕妇产前血清IgG抗A（B）抗体效价对ABO新生儿溶血病（HDN）的诊断意义.方法：466例夫妇血型不合的O型血孕妇接受IgG抗A（B）抗体效价检测,对其中IgG抗A（B）抗体效价≥1∶ 64孕妇所生的新生儿进行ABO-HDN血型血清学检测.结果：466例O型RH（D）阳性孕妇中,IgG抗A（B）抗体效价1∶ 32或以下、1∶ 64、1∶ 128、1∶ 256、1∶512或以上分别有83例（18%）、123例（26%）、94例（20%）、86例（18%）、80例（17%）.O-A组、O-B组、O-AB组效价≥1∶ 64者分别占89%、76%、76%, O-A组效价≥1∶64者所占比例高于 O-B组及O-AB组（P＜0.05）,HDN发病率随孕妇血清IgG抗A（B）抗体效价增加而升高,组间比较差异均有统计学意义（P＜0.05或0.01）.结论：夫妇血型不合O型血孕妇的血清IgG抗A（B）抗体效价可作为ABO-HDN的筛查指标,产时应尤其密切观察A型血新生儿的临床表现,做到ABO-HDN的早期诊断、早期治疗.     

血型抗体与新生儿溶血病

目的探讨ABO-HDN血型不合孕妇血清IgG抗A(B)效价与ABO-HDN的关系。方法对1 632例O型孕妇血清IgG抗A(B)效价检测及抗体分型分析。结果1 632例孕妇血清中IgG抗A(B)≥1/64者249例,占15.3%;ABO-HDN发生率随IgG抗A(B)效价升高而上升;HDN与妊娠史的频率有关,随着年龄上升,孕妇个体IgG抗A(B)抗体效价也随之上升。结论夫妇间ABO血型不合者应及时检查产前血型抗体水平;预防不良妊娠的发生;IgG抗A(B)效价的高低与HDN的发病率成正比;孕妇血清IgG抗A(B)效价≥1/64需定期检测抗体效价水平及时用药降低抗体效价,预防新生儿溶血病的发生。     

微柱凝胶技术在孕妇IgG抗体A（B）抗体测定中的应用

新生儿溶血病（HDN）是指母婴血型不合引起的胎儿或新生儿免疫溶血性疾病。ABO血型不合引起HDN在国内较多见．其中最多见的是母亲是O型．胎儿为A型或B型是引起HDN的最主要原因。随着孕妇血清IgG抗A（B）抗体效价的增高,HDN发生率增加,溶血程度加重。准确测定孕妇血清IgG抗A（B）抗体效价．可为产前诊断和预防ABO—HDN提供依据。     

O型血孕妇血清中IgG抗(A)B抗体效价对ABO新生儿溶血病的诊断意义

目的研究O型血孕妇血清中IgG抗(A)B抗体效价及对ABO新生儿溶血病(HDN)的诊断意义。方法将446例O型孕妇(丈夫血型非O型)接受IgG抗A(B)抗体效价检测,并对孕妇所生的新生儿进行HDN血清学检测,包括新生儿ABO血型检测、Rh(D)血型检测、HDN三项血清试验。结果 446例O型RH(D)阳性孕妇中,IgG抗A(B)抗体效价小于或等于1∶32、1∶64、1∶128、1∶256、≥1∶512分别有77例(17%)、117例(26%)、92例(21%)、84例(19%)、76例(17%),呈现正态分布。母婴血型O-A组效价大于1∶32者所占比例明显高于O-B组及O-AB组(P<0.05),而O-B组与O-AB组间差异无统计学意义(P>0.05)。HDN发病率随孕妇血清IgG抗A(B)抗体效价增加而升高,高一级效价与低一级效价组间比较差异均有统计学意义(P<0.05)。结论 O型血孕妇的血清IgG抗A(B)抗体效价可作为ABO HDN的诊断指标,产时应尤其密切观察A型血新生儿的临床表现,做到ABO HDN的早期筛查、早期诊断以及早期治疗。     

妊娠妇女产前不规则抗体检测分析

目的 检测妊娠妇女血清中IgG抗A(B)及Rh血型抗D抗体效价,探讨妊娠妇女不规则抗体筛查在新生儿溶血病预防中的意义.方法 常规检测夫妇ABO及RhD血型,对夫妇ABO及Rh血型不合的妊娠妇女血清进行不规则抗体筛选及特异性鉴定.结果 在421例夫妇ABO血型不合的妊娠妇女血清中,IgG抗A(B)效价大于或等于1∶64者168例(39.9%),在2例RhD阴性妊娠妇女中检出抗D抗体1例(50.0%).结论 产前对夫妇进行ABO、RhD血型及IgG抗A(B)和抗D效价检测,发现异常及时进行治疗,可减少因母婴血型不合而产生的新生儿溶血病的发生率;血型不完全抗体检测卡检测IgG抗A(B)及抗D抗体效价,操作简便,结果准确.     

O型孕妇血型抗体效价与新生儿溶血发病率的关系分析

目的：研究。型RhD阳性孕妇（其丈夫为非O型）血清IgG抗-A（抗-B）抗体效价与新生儿溶血病（HDN）的关系。方法：应用微柱凝胶技术对382例O型RhD阳性孕妇进行了免疫性IgG抗A（B）抗体效价检测及对其新生儿进行HDN（①新生儿ABO、Rh系统定型;②新生儿直抗实验;③游离IgG测定;④放散实验）的检测。结果：382例O型RhD阳性孕妇中IgG抗-A（B）效价〈64者330例（占总数86．39％）,抗体效价≥64者13．61％。其中发生HDN5例,抗-A3例,抗-B12例,总发生率1．31％。结论：夫妇血型不合应及时检测孕妇IgG抗体,随着孕妇体内IgG抗体效价的增高,新生儿ABO溶血病的发病率也随之升高。孕妇产前应定时进行IgG抗体检测,了解效价与新生儿溶血病发病率之间的关系,对于预防新生儿溶血病极为有效。     

应用ROC曲线评价产前IgG抗A(B)效价检测对早期诊断ABO新生儿溶血病的价值

目的 研究O型孕妇产前血清IgG抗A(B)效价对早期诊断ABO新生儿溶血病(HDN)的价值.方法 采用微柱凝胶法检测704例夫妻血型不同的O型孕妇产前血清IgG抗A(B)效价,用红细胞(RBC)直接抗人球蛋白试验、RBC抗体放散试验、血清游离抗体测定等3项试验确定患儿是否患有HDN,用受试者工作特性(ROC)曲线进行分...     

探讨微柱凝胶法在检测孕妇ABO血型IgG抗体效价中的应用

目的初步探讨微柱凝胶法技术在检测O型血孕妇血清中IgG抗A（B）血型抗体水平中的应用价值,以预防新生儿溶血病的发生。方法应用微柱凝胶法技术和抗球蛋白法分别测定O型血孕妇IgG抗A（B）抗体效价。结果 1 798例夫妻中,微柱凝胶法和抗球蛋白法检测O-A组合IgG抗A效价≥1∶64者分别为53例、51例;O-B组合IgG抗B效价≥1∶64者分别为32例、29例;O-AB组合IgG抗A抗B效价均≥1∶64者分别为6例、7例,2种方法差异无统计学意义（P〉0.05）。结论微柱凝胶免疫检测法可快捷准确检测O型血孕妇血清IgG抗A（B）抗体的效价,对预防新生儿溶血病的发生具有重要临床意义。     

Antibodies to histo-blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categories

Isotypes and IgG subclasses of ABO antibodies from sera of 235 healthy blood donors were determined by an enzyme-linked immunosorbent assay (ELISA). Synthetic A and B trisaccharide-bovine serum albumin glycoconjugates were used for coating and monoclonal antibodies for the detection of heavy chain isotypes. Hemagglutination titers were determined in addition. Blood donors were between 20 and 67 years old, and at least 10 sera per 10-year age category and ABO blood group were included in this study. Antibody concentrations were expressed as a percentage of an internal standard, and sera with subclass-restricted anti-A and/or anti-B (anti-A/B) responses were used to normalize the ELISA values of IgG subclasses. A good correlation between the sum of the four subclasses and the total anti-A/B IgG values (rs = 0.81 for anti-A and 0.84 for anti-B) was obtained. IgG1 and IgG2 were the most predominant subclasses, but were found in various proportions in different individuals. Donor-to-donor variation exceeded age-related changes for all measured parameters. The correlation of anti-A IgM, IgG, IgA, and their sum with the agglutination titers was significant and revealed rs values of 0.70, 0.65, 0.65, and 0.80, respectively. For anti-B as well, the correlation of ELISA values with the agglutination titer was best when all three isotypes were added. We conclude that anti-A/B IgA, together with IgM and IgG, substantially contributes to the agglutination reaction. Potentially autoreactive antibodies were detected in sera of blood groups A, B, and AB.     

微柱凝胶技术检测521例O型血孕妇IgG A(B)抗体效价

目的研究血型为O型的孕妇产前IgG A(B)抗体效价,以预防新生儿溶血病的发生。方法采用微柱凝胶法测定IgG抗-A(B)效价。结果 521例孕妇中,IgG抗-A(B)效价大于或等于1∶128者有288例,占49.66%。其中IgG抗-A效价大于或等于1∶128者有161例,占IgG抗-A总人数的54.03%,IgG抗-B效价大于或等于1∶128者有127例,占IgG抗-B总人数的45.04%。结论通过微柱凝胶免疫检测法检测孕妇血清血型抗体IgG效价能有助于诊断新生儿溶血病,指导临床干预措施。     

The characteristics of ABO antibodies in group O Thai blood donors

This study aimed to characterize anti-A and anti-B hemolysins, IgM, and IgG titers in Thai blood donors. Altogether, 300 serum samples from group O donors at the National Blood Centre, Thai Red Cross Society, were screened for anti-A and anti-B hemolysins and treated with 0.01 M dithiothreitol to characterize IgM and IgG titers by standard tube technique. Antibody titers were compared with hemolysis grade. Male and female ratio = 1:1.3 and ages ranged from 17 to 60 years. The overall prevalence of anti-A and anti-B hemolysins was 69%. Anti-A and anti-B hemolysins comprised 18.3% and 16.7%, respectively and 34% had both antibodies. High titers of anti-A hemolysins were associated with females (P< 0.05), and only anti-B IgM titers were associated with age (P< 0.05). Interestingly, the association of anti-A IgM titers, anti-A IgG titers, and hemolysin grade was demonstrated (P< 0.05). A significant association between hemolysin grade and anti-B IgM titers was found (P< 0.05). The prevalence of anti-A and anti-B hemolysins and high titers of IgM and IgG in Thais are high. Hemolysin grade showed significant associations with IgM titers; therefore, when providing ABO-incompatible platelet transfusion, especially for female plateletpheresis donors, IgM high titers of anti-A and anti-B screening is suggested.     

新生儿ABO溶血病患儿母亲孕期IgG抗A/B效价的动态监测

目的动态监测O型孕妇不同孕期血清IgG抗A/B效价,为更加准确地预测新生儿ABO溶血病的发生提供诊断依据。方法通过对232例新生儿ABO溶血病的患儿母亲孕早期和孕晚期IgG抗A/B效价的动态监测,观察这类孕妇抗体效价的分布情况、变化率和变化幅度。结果这类孕妇的孕早期和孕晚期IgG抗A/B效价大多分布在≥1∶256,其中绝大多数孕妇（O-A：94.9%,O-B：95.8%）孕晚期的IgG抗A/B效价较孕早期有不同程度的升高;以升高2个滴度为主（O-A：46.3%,O-B：44.8%）。有11例其孕晚期的IgG抗A/B效价较孕早期无变化甚至发生降低,这11例孕妇孕早期的IgG抗A/B效价就偏高,主要分布在≥1∶512。结论动态监测O型孕妇不同孕期血清IgG抗A/B效价十分必要,可以将孕晚期抗体效价较孕早期升高2个滴度或以上作为提示ABO溶血的指标。     

High titers of anti-A1 and anti-B antibodies among Peruvian group O platelet donors

Critical antibody titers have been described as factors associated with hemolysis in ABO plasma-incompatible platelet (PLT) transfusions. This study was carried out to describe the frequency of high-titers anti-A and antiB IgM and IgG antibodies in group O apheresis platelet donors, and to explore differences according to the donor characteristics. A cross-sectional study was carried out at the Blood Bank of a National Hospital in Peru from January to March 2019. IgM and IgG antibodies against A1 and B antigens were quantified in 339 platelet donors using the direct hemagglutination technique and the solid-phase adherence technique, respectively. For analysis purposes, two cut-off points; ≥128 and ≥64, were used to define a critical titer for IgM due to a lack of consensus. An IgG titer of ≥256 was also defined as critical. Of the donors, 22.1 % had critical IgM titers when the cut-off point was defined as ≥128. However, when the IgM cut-off was ≥64, the frequency of platelet donors with critical titers increased to 54.0 %. The frequency of donors with critical IgG titers was 23.5 %. Higher IgG titers were associated with female donors while higher IgM titers were negative associated with age. One in two or three platelet donors, depending on the cutoff point used to define a critical IgM titer, had at least one critical titer of anti-A or anti-B antibodies. Early identification of platelet donors with critical antibody titers could prevent passive transfusion of ABO antibodies to non-isogroup recipients.     

Age dependency of ABO histo-blood group antibodies: reexamination of an old dogma

Current textbooks for transfusion medicine state that anti-A and/or anti-B (anti-A/B) agglutination titers–and thus the respective antibody concentrations–reach their maximum in individuals 5 to 10 years old and then gradually decline with the increasing age of the individual. This statement is largely based on a study by Thomsen and Kettel that dates to 1929. In the present article, ABO antibodies in sera of 175 healthy persons aged 61 to 97 years, as well as sera of 170 newborn infants and children aged 0 to 17 years, were analyzed. Microhemagglutination tests were performed with all sera and complemented by ABO enzyme-linked immunosorbent assays to measure the immunoglobulin class (IgM, IgG, and IgA) of the anti-A/B. As in a previous study using sera of persons aged 20 to 67 years, individual differences exceeded age-related changes for all variables. Median values of IgG and IgA anti-A/B were elevated in elderly persons of blood group O, whereas no significant changes were observed in other variables. In particular, the decrease in agglutination titers with the increasing age of the individuals was far less pronounced than previously described; even in sera of persons aged 90 to 97 years, median agglutination titers of 128 were found. Results in the sera of children confirm previously reported data that agglutination titers and IgM anti-A/B reached adult levels at the age of 5 to 10 years.     

MB-P对血浆部分细胞因子与ABO血型抗体活性影响

目的研究亚甲蓝光化学病毒灭活法(MB-P)对血浆SCF、TPO、PF4与GPⅡb/Ⅲa活性与ABO血型抗体活性的影响。方法应用ELISA方法对MB-P制备前后血浆SCF、TPO、PF4与GPⅡb/Ⅲa活性进行检测;应用血型血清学检测方法对MB-P制备前后血浆IgM抗-A、IgM抗-B与IgG抗-A、IgG抗-B活性进行检测。结果 MB-P制备血浆SCF、TPO、PF4与GPⅡb/Ⅲa活性均有不同程度下降,分别为2.59±2.71,248.54±49.01,12.02±3.21,10.21±9.97;与制备前相互比较有统计学意义(P0.05)。另外,MB-P制备后血浆红细胞IgM抗-A、IgM抗-B与IgG抗-A、IgG抗-B效价也有不同程度下降,与制备前相互比较有统计学意义(P0.05)。结论应用MB-P制备血浆须高度重视部分细胞因子与红细胞ABO血型抗体变化情况,确保临床输血安全性与有效性。